Grant: Alliance Grants
University of British Columbia
$50,000.00
ELECTRA platform: Electrochemical-based Aptasensor for early detection of COVID-19_x000d_ _x000d_
FY 2020-21
Summary
The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly infectious. Therefore, diagnostic testing for COVID-19 is critical for tracking the virus, informing case management and suppressing viral transmission. Current tests for COVID-19 rely on laboratory-based viral gene identification or antibody testing; however, these tests are expensive, time-consuming and require specialized equipment and trained personnel. Hence, there is a worldwide diagnostic gap for COVID-19 testing that is fast, reliable and affordable. Current testing protocols also overlook a key source of COVID-19 biomarkers that can rapidly predict infection and complement viral detection by using the body's inflammatory response through the production of immune proteins called cytokines. The body's cytokine response occurs within 24 hours of infection. The hyperproduction of these cytokines, known as a cytokine-storm, has been linked to post-recovery health complications such as pneumonia. Therefore, a diagnostic device that simultaneously detects the viral pathogen and verifies host cytokine biomarkers would provide a two-in-one diagnostic solution for the early detection of COVID-19. However, there is no such real-time, label-free, specific and sensitive diagnostic solution that can achieve this on a single platform. The proposed research project and partnership aim to address this technology gap through the development of a two-in-one COVID-19 viral and immune detection platform - the ELECTRA platform (short for ELECTRochemical-based Aptasensor). The sensor will be configured as a field-effect transistor in which a graphene-based conducting channel (GFET) will be functionalized with a selected group of aptamers with high affinity towards SARS-CoV-2 structural proteins and COVID-19 elevated cytokines. It will be integrated into a prototype of the ELECTRA real-time detector. The proposed approach is a unique technique for the early detection of COVID-19 and also has the potential to be applied for the diagnostics of other viral infections.
Program
Alliance Grants
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
553523-2020
Name nom
Hoorfar, Mina
Department département
Okanagan - Engineering, School of
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
ELECTRA platform: Electrochemical-based Aptasensor for early detection of COVID-19_x000d_
_x000d_
Keyword
NSERC
Application summary
The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly infectious. Therefore, diagnostic testing for COVID-19 is critical for tracking the virus, informing case management and suppressing viral transmission. Current tests for COVID-19 rely on laboratory-based viral gene identification or antibody testing; however, these tests are expensive, time-consuming and require specialized equipment and trained personnel. Hence, there is a worldwide diagnostic gap for COVID-19 testing that is fast, reliable and affordable. Current testing protocols also overlook a key source of COVID-19 biomarkers that can rapidly predict infection and complement viral detection by using the body's inflammatory response through the production of immune proteins called cytokines. The body's cytokine response occurs within 24 hours of infection. The hyperproduction of these cytokines, known as a cytokine-storm, has been linked to post-recovery health complications such as pneumonia. Therefore, a diagnostic device that simultaneously detects the viral pathogen and verifies host cytokine biomarkers would provide a two-in-one diagnostic solution for the early detection of COVID-19. However, there is no such real-time, label-free, specific and sensitive diagnostic solution that can achieve this on a single platform. The proposed research project and partnership aim to address this technology gap through the development of a two-in-one COVID-19 viral and immune detection platform - the ELECTRA platform (short for ELECTRochemical-based Aptasensor). The sensor will be configured as a field-effect transistor in which a graphene-based conducting channel (GFET) will be functionalized with a selected group of aptamers with high affinity towards SARS-CoV-2 structural proteins and COVID-19 elevated cytokines. It will be integrated into a prototype of the ELECTRA real-time detector. The proposed approach is a unique technique for the early detection of COVID-19 and also has the potential to be applied for the diagnostics of other viral infections.